Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 2/20 | 0.59 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MASP2 | O00187 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679914 | 0.84 | HTR3E (0.53) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL5924157 | 0.84 | HTR3E (0.53) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL8239403 | 0.84 | FABP6 (0.72) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL11373844 | 0.83 | FABP6 (0.50) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL11373862 | 0.83 | FABP6 (0.50) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL13619367 | 0.80 | FABP6 (0.51) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL13631341 | 0.80 | FABP6 (0.51) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL11146398 | 0.79 | FABP6 (0.46) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL23419203 | 0.77 | FABP6 (0.45) | FABP6PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL1171206 | 0.77 | ALDH1A1 (0.67) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240116897-A1 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-04-11 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4269394-A1 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2023-11-01 | — | — | EP | disclosed |
| CN-116829542-A | Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient | 韩国化学研究院 | 2023-09-29 | — | — | CN | disclosed |
| US-5712255-A | VIRICIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-01-27 | — | — | US | disclosed |
| US-5705490-A | TREATMENT OF HERPES OR CYTOMEGALOVIRUS WITH BENZIMIDAZOLE DERIATIVES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654283-A | HERPES VIRUS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646125-A | Polysubstituted benzimidazoles as antiviral agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-07-08 | — | — | US | disclosed |
| US-5574058-A | Polysubstituted benzimidazoles as antiviral agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0556334-A4 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | UNIV MICHIGAN (US) | 1995-03-29 | — | — | EP | disclosed |
| US-5360795-A | Treating cytomegalo virus and herpes simplex viruses | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-11-01 | — | — | US | disclosed |
| WO-1994008456-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0556334-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1993-08-25 | — | — | EP | disclosed |
| WO-1992007867-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | FABP6 3687/4885PLAU 3305/4885HTR3E 2775/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | FABP6 3528/4885PLAU 3142/4885HTR3E 3064/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | FABP6 4120/4885PLAU 3290/4885HTR3E 2249/4885 |
| US-20240116897-A1 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | SIRT7, SIRT1, BRD7 | FABP6 1495/4885PLAU 2944/4885HTR3E 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.